LLY

1,043.77

+0.35%↑

JNJ

243.66

-0.28%↓

ABBV

232.22

+3.02%↑

NVS

162.26

+0.56%↑

MRK

121.54

+0.79%↑

LLY

1,043.77

+0.35%↑

JNJ

243.66

-0.28%↓

ABBV

232.22

+3.02%↑

NVS

162.26

+0.56%↑

MRK

121.54

+0.79%↑

LLY

1,043.77

+0.35%↑

JNJ

243.66

-0.28%↓

ABBV

232.22

+3.02%↑

NVS

162.26

+0.56%↑

MRK

121.54

+0.79%↑

LLY

1,043.77

+0.35%↑

JNJ

243.66

-0.28%↓

ABBV

232.22

+3.02%↑

NVS

162.26

+0.56%↑

MRK

121.54

+0.79%↑

LLY

1,043.77

+0.35%↑

JNJ

243.66

-0.28%↓

ABBV

232.22

+3.02%↑

NVS

162.26

+0.56%↑

MRK

121.54

+0.79%↑

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Avatud

SektorTervishoid

19.99 5.88

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.93

Max

20.08

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -127M
Töötajad	517
EBITDA	-12M -134M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+57.29% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	25. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	1B 3.3B
Eelmine avamishind	14.11
Eelmine sulgemishind	19.99

Uudiste sentiment

By Acuity

25%

75%

49 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

13.355 / 16.44 Toetus ja vastupanu

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. veebr 2026, 23:57 UTC

Kuumad aktsiad

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12. veebr 2026, 23:35 UTC

Tulu

Suurimad hinnamuutused turgudel

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12. veebr 2026, 23:28 UTC

Tulu

Applied Materials Profit Rises on Soaring AI Demand -- Update

12. veebr 2026, 21:47 UTC

Tulu

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13. veebr 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12. veebr 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12. veebr 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12. veebr 2026, 23:33 UTC

Tulu

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12. veebr 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12. veebr 2026, 22:55 UTC

Tulu

Kuumad aktsiad

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12. veebr 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12. veebr 2026, 22:23 UTC

Tulu

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12. veebr 2026, 22:00 UTC

Tulu

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12. veebr 2026, 22:00 UTC

Tulu

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12. veebr 2026, 21:57 UTC

Tulu

XP 4Q Rev BRL4.95B >XP

12. veebr 2026, 21:52 UTC

Tulu

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12. veebr 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. veebr 2026, 21:47 UTC

Tulu

Morningstar 4Q Rev $641M >MORN

12. veebr 2026, 21:39 UTC

Tulu

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. veebr 2026, 21:38 UTC

Tulu

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

57.29% tõus

12 kuu keskmine prognoos

Keskmine 32.78 USD 57.29%

Kõrge 40 USD

Madal 25 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

13.355 / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

49 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.